



UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: WSTR-0014C

Inventors: Ramin Shiekhattar

Serial No.: 10/634,574

Filing Date: August 5, 2003

Examiner: Not Yet Assigned

Group Art Unit: 1645

Title: Methods for Regulating BRCA1-BRCA2-
Containing Complex Activity

I, Jane Massey Licata, Registration No. 32,257,
certify that this correspondence is being deposited
with the U.S. Postal Service as First Class mail in
an envelope addressed to the Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450

On this date: December 17, 2003

Jane Massey Licata
Jane Massey Licata, Registration No. 32,257

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified

application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

() In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is attached hereto; or

() The fee of \$180.00 as set forth in §1.17(p) is attached.

() In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I) (1).

(XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.


() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,



Jane Massey Licata
Registration No. 32,257

Date: December 17, 2003

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce	Docket No. WSTR-0014C	Serial No. 10/634,574
	Applicant Ramin Shiekhattar	
	Filing Date August 5, 2003	Group 1645

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	AA	4,736,866	4-12-88	Leder et al.	800	1
	AB	4,870,009	9-26-89	Evans et al.	435	70

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES NO	

EXAMINER

DATE CONSIDERED

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce		Docket No. WSTR-0014C	Serial No. 10/634,574
		Applicant Ramin Shiekhattar	
		Filing Date August 5, 2003	Group 1645
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	BA	Goeddel D.D., et., Gene Expression Technology, Academic Press, San Diego, CA 1991	
	BB	Sambrook et al., Molecular Cloning:A Laboratory Manual, 3rd Edition, Cold Spring Harbor Laboratory Press 2000	
	BC	Remington:The Science and Practice of Pharmacy, Alfonso R. Gennaro, editor, 20th ed. Lippincott Williams & Wilkins:Philadelphia, PA 2000	
	BD	Chen et al., "Autoubiquitination of the BRCA1 BARD1 RING Ubiquitin Ligase", J. Biol. Chem. 2002 277(24):22085-22092	
	BE	Fisch et al., "The chromosomal translocation t(X;14)(q28;q11) in T-cell pro-lymphocytic leukaemia breaks within one gene and activates another", Oncogene 1993 8:3271-3276	
	BF	Hashizume et al., "The RING Heterodimer BRCA1-BARD1 Is a Ubiquitin Ligase Inactivated by a Breast Cancer-derived Mutation", J. Biol. Chem. 2001 276(18):14537-14540	
	BG	Li et al., "Identification of a Brain-And Reproductive-Organs-Specific Gene Responsive to DNA Damage and Retinoic Acid", Biochemical and Biophysical Research Communications 1995 206(2):764-774	
	BH	Lorick et al., "RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination", Proc. Natl. Acad. Sci. USA 1999 96:11364-11369	
	BI	Ruffner et al., "Cancer-predisposing mutations within the RING domain of BRCA1:Loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity", Proc. Natl. Acad. Sci. USA 2001 98(9):5134-5139	
EXAMINER		DATE CONSIDERED	